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Hypoxia-driven splicing into noncoding isoforms regulates the
DNA damage response
Danish Memon1, Keren Dawson1, Christopher SF Smowton2, Wei Xing2, Caroline Dive3 and Crispin J Miller1
Tumour hypoxia is associated with poor patient outcome and resistance to therapy. It is accompanied by widespread changes in
gene expression mediated largely through the transcription factors HIF1/2/3α. Hypoxia impacts on multiple pathways throughout
the cell and has widespread effects on phenotype. Here we use sample-specific annotation approaches to determine the
changes in transcript architecture that arise as result of alternative splicing in hypoxic cells. Using in vivo data generated from a time
course in reduced oxygenation we identified genome-wide switching between coding and noncoding isoforms, including a
significant number of components of the DNA damage response pathway. Notably, HDAC6, a master regulator of the cytotoxic
response, and TP53BP1, which sits at the nexus of the double-strand break repair pathway, both underwent a marked transition
towards an intron-retention pattern with a concomitant decline in protein levels. These transitions from coding to noncoding
isoforms were recapitulated in a large and independent cohort of 499 colorectal samples taken from The Cancer Genome
Atlas (TCGA). The set of altered genes was enriched for multiple components of the Fanconi Anaemia, nucleotide excision and
double-strand break repair pathways, and together correlating with tumour status at last contact. Altogether, these data
demonstrate a new role for hypoxia-driven alternative splicing in regulating DNA damage response, and highlight the importance
of considering alternative splicing as a critical factor in our understanding of human disease.
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INTRODUCTION
Hypoxia occurs within the majority of solid tumours and is
associated with poor patient outcome and chemo- and
radioresistance.1,2 Hypoxia arises both because disorganisation
within tumour microvasculature lengthens intracapillary
distances beyond the diffusion range of oxygen and because
transient disruptions to blood flow provoke periods of acute
oxygen starvation. Hypoxia has multiple impacts on tumour biology
including selection of altered cell signalling, angiogenesis, vascu-
logenesis, changes in central metabolism, suppression of immune
reactivity, enhanced receptor tyrosine kinase signalling and down
regulation of DNA repair pathways, promotion of prosurvival
phenotypes and increased proclivity for invasion and metastasis;3,4
extensively reviewed in references 5,6. Many of these hypoxia
responses are characterised by widespread alterations in transcrip-
tion profiles driven largely (but not exclusively) by stabilisation of
the transcription factor subunit hypoxia inducible factor 1α
(HIF1α).7,8 Hypoxia mediated transcriptional regulation is also
controlled by other factors including HIF2α9 and HIF3α.10
In addition, signalling through both the growth factor receptor
pathways (phosphatidylinositol 3-kinase; PI3K, ERK) and energy
depletion pathways (5-AMP-activated protein kinase; AMPK) con-
verge on the tuberous sclerosis complex (TSC1/2) leading to
complex patterns of spatial and temporal regulation in response to
stress. These signals feed into mechanistic target of rapamycin
(mTOR), which, in the context of hypoxia, leads to the rapid
suppression of protein synthesis,11 presumably in order to conserve
energy.12 Levels of hypoxia vary between and within tumours,
correlate with patient outcomes, and can lead to differences in
response to therapy.13 A better understanding of heterogeneity
in hypoxia-driven changes in gene expression will therefore inform
strategies for precision medicine,14 raising the need for reliable
biomarkers of tumour hypoxia. To this end, a number of groups
have developed multiplex gene expression signatures with the
intention of better reflecting the multiplicity of pathways involved
in the hypoxic response, e.g., references 13,15,16.
In recent years, advances in expression profiling have revealed
substantial levels of alternative splicing within the human
genome, such that the majority of protein-coding genes are
now known to express multiple isoforms (median isoform count
per protein coding gene in ENSEMBL 74: 5), of which 44%
are annotated as noncoding (63,816: ‘noncoding’; 81,715: ‘protein-
coding’). Despite their prevalence, the majority of these transcripts
have yet to be characterised, raising the question of how much of
this ‘dark matter’ is functional, and how much is simply a
consequence of aberrant splicing and a passive by-product of
gene expression.
Given the widespread alterations in transcript expression that
arise in response to changes in oxygen levels, we speculated that
similar systematic alterations in splicing might add further levels
of transcriptional control. We therefore exploited the increased
precision offered by RNA sequencing to investigate how hypoxia
affects alternative splicing, since earlier studies using 3′ IVT arrays
were not able to characterise the transcriptome at this level of
precision. We used de novo sample-specific annotation strategies
to investigate changes in exon structure alongside multiple
events including intron retention and alterations to 5′ and 3′
gene boundaries. We applied these novel annotation approaches
both to a time course of colorectal cancer cells in reduced oxygen
and to reanalyse a large cohort of colorectal samples from TCGA.
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RESULTS
Systematic resplicing of the transcriptome in response to hypoxia
RNA deep sequencing over a time course of enforced hypoxia
was used to identify changes in coding and noncoding RNA
levels in HCT116 cells. Cells were collected at 0, 1, 2, 24 h in
reduced oxygen (1% O2) and poly(A) RNA sequenced using
100mer paired-end strand-specific Illumina sequencing. FACS
analysis revealed no significant effect on cell proliferation or
apoptosis at 24 h in response to hypoxia (Supplementary
Figure 1). Data were aligned and exon structure determined
using a multistage pipeline including DEXSeq,17 Mapsplice18 and
Cufflinks19,20 to identify significant events such as exon skipping
and intron retention (Supplementary Figure 2; Supplementary
Methods). This generated an augmented catalogue of transcripts
in which novel isoforms identified by Cufflinks were amalgamated
with existing annotations from ENSEMBL, before splicing
changes were identified through Multivariate Analysis of
Transcript Splicing (MATS).21
Of the 53,936 transcripts identified, 52,733 mapped to 15,334
genes in ENSEMBL (v74)22 while 1,203 (1,155 genes) were
unannotated (Supplementary Table 2). In keeping with previous
reports,15 12% of protein-coding genes exhibited gene-level
changes within the time course (N= 2,387), and included multiple
genes associated with hypoxia, glycolysis and MAPK signalling
(Supplementary Table 3; Supplementary Figure 2). At the isoform
level, 9,222 (60%) of genes were present in at least 2 isoforms, of
which 4,982 (54%) were predicted to code for isoforms with at
least one novel fragment, and therefore sharing only a subset of
known splice sites (Supplementary Table 2). Multiple changes to
within the coding sequence were identified using Cuffdiff.
These included multiple kinases (CLK4, MARK4, ACVR2B, MAP3K3,
MAP3K8, STK32C and SGK494) and 2 phosphatases (PPP5C,
PPP3CB; see Supplementary Table 4; Supplementary Figure 4
which also lists loci with alternate 5′ ends).
Splicing events were frequent and diverse. 29% (N= 869/2,949)
of spliced genes were predicted by MATS to exhibit multiple
concurrent modifications (Figure 1a), including a substantial
increase in the number of retained introns, increased exon
skipping, increased usage of alternate 5′ and 3′ splice sites
(Figure 1b; Supplementary Table 4; Supplementary Figure 5), and a
global shift towards expression of retained intron transcripts
(Figure 1c). Genes involved in exon skipping and inclusion
exhibited high enrichment for Cell cycle (GO:0007049) and RNA
splicing (GO:0008380). The RNA splicing pathway was also
enriched for genes that exhibited increased intron retention in
hypoxia, suggestive of a feedback loop in which components
of the alternative splicing machinery are themselves regulated
in part by changes to splicing patterns. Importantly, genes
associated with Response to DNA Damage Stimulus and
DNA repair pathway also exhibited increased intron retention
(Benjamini and Hochberg corrected P valueo0.05).
Confirmation that retained intron expression regulates expression
of HDAC6 and TP53BP1 protein levels
In addition to changes between protein coding isoforms
(Supplementary Figure 6), 29% of genes switched from a protein-
coding to noncoding major isoform, with the majority of events
(199/343) leading to the expression of a noncoding isoform as the
primary transcript under hypoxia (Supplementary Table 5). Of these,
most changes were driven by intron retention (88/132) and were
consistent with an overall increase in the expression of retained-
intron transcripts after 24 h in hypoxia (P valueo0.001; Figure 1b,c).
We hypothesised that this might provide a previously
unreported mechanism by which cells could modulate protein
levels in response to hypoxia, and therefore sought to confirm
that a switch towards a noncoding isoform was indeed associated
with altered protein levels. Two notable genes with
substantial changes in intron retention were HDAC6 and TP53BP1
(Figure 2a,d). HDAC6 is a class IIb histone deacetylase with an
unusually diverse set of substrates that include multiple cytosolic
proteins such as HSP90. HDAC6 inhibition has been associated
with the processing of protein aggregates, the misfolded protein
stress response pathway, and more generally as a master
regulator of cytotoxic stress,23,24 including its involvement in the
ubiquitination and deacetylation of the mismatch repair (MMR)
protein MutS protein homologue 2 (MSH2).25 Levels of intron
expression at the locus increased in hypoxic conditions and
were accompanied by a significant decline in protein levels
(Figure 2b,c). TP53BP1 also exhibited an increase in intron
retention and an associated decline in protein levels (Figure 2e,
f). It sits at the nexus of the double-strand break repair pathway
where it performs a number of roles, including binding to P53,
leading to enhanced transactivation and increased levels of P21,26
interacting with chromatin to promote DNA repair,27 and
recognising H4K20me2 and H2AK15ub histone marks arising from
double-strand break signalling.28 TP53BP1 has also been shown to
Figure 1. Isoform switching in hypoxia increases the abundance of unproductive transcripts. (a) Multiple splicing events affect the majority of
alternatively spliced genes. A3SS, alternative 3′ start site; A5SS, alternative 5′ start site; AFE, alternative first exon; ALE, alternative last exon;
MXE, mutually exclusive exons; RI, retained intron; SE, spliced exon. (b) Inclusion or exclusion of exons in response to hypoxia, detected by
MATS. Categories as a. (c) Overall expression levels of genes that switch between ‘protein-coding’ and ‘retained-intron’ major isoform between
normoxia and hypoxia.
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cooperate with RIF1 and MAD2L2 (Rev7)23 to modulate non-
homologous end joining and genetic stability. These data are
therefore particularly interesting in the context of a ‘mutator
phenotype’ in which a shift to increased genetic instability is
postulated to promote clonal diversity within a tumour.24
Colorectal tumours express high proportion of unproductive
transcripts
Having identified a new role for alternative splicing in regulating
protein levels in response to hypoxia, we asked whether similar
changes were observed in human tumours. We analysed RNA-seq
data derived from 458 colorectal tumour samples and 41 normal
tissues obtained from The Cancer Genome Atlas (TCGA).29 The
samples included AJCC pathologic staging (Stage I–Stage IVB),
metastatic staging (M0, M1 and MX) and therefore included
both patients with early-localised disease as well as metastasis.
No information was available about previous treatment with
radiotherapy or chemotherapy for the majority of patients.
As the TCGA data were processed on two different platforms
(an Illumina HiSeq 2000 and an Illumina GAII), we tested whether
there were significant differences in mapping rates to introns and
exons between the two platforms. No inconsistencies were
identified between the two platforms, and major isoforms for each
gene were assigned independently for each sample, further
mitigating against batch effects. In total, 4,303 genes were found
to switch between coding and noncoding major isoforms in at least
5% of samples (Figure 3a; Supplementary Table 6). Unsupervised
clustering of these data by major isoform coding/noncoding status
revealed three major clusters (Figure 3a). The proportion of
noncoding major-isoforms correlated well with available relapse
data, with tumours from patients who were subsequently defined
as ‘tumour free’ at last contact expressing fewer noncoding
major-isoforms than those defined as ‘with tumour’ (tumour-free:
916; with tumour: 1945; P value o0.01; Figure 3b). As
expected, many of these also switched between coding and
Figure 2. Changes in HDAC6 and TP53BP1 transcript and protein levels in response to hypoxia. (a) Expression across introns in HDAC6 at 0, 2,
24 h following a shift to reduced oxygen (1%). Colour represents log2 fold-change. (b) HDAC6 protein levels as determined by western blot
(c). (d–f) TP53BP1 exhibits similar patterns of expression.
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noncoding isoforms in the HCT116 cell line data (P value o0.01;
hypergeometric test), suggesting that a significant proportion of
these changes are driven by changes in oxygenation status within
the tumours. Interestingly, 750 genes changed in major-isoform
status from coding to noncoding between these two classes
(Figure 3c; Supplementary Table 6); however, switching to a
noncoding isoform was not significantly associated with a global
change in overall transcription levels associated with these loci
Figure 3. Switch from coding to noncoding transcripts is a signature of colorectal tumours. (a) Change in major isoform class between
‘tumour-free’ and ‘with tumour’ samples in TCGA colorectal carcinomas; Orange: enriched in ‘with tumour’ samples. (b) Unsupervised
clustering of colorectal tumour samples based on major isoform type: NMD, ‘nonsense-mediated decay’; Processed, ‘processed transcript’;
RI, ‘retained Intron’. (c) Proportion of noncoding major isoforms detected across colorectal tumour samples stratified by patient status at last
contact: ‘tumour free’ (purple) and ‘with tumour’ (green). Data from TCGA. (d) Average expression level of genes changing from coding to
noncoding major isoform (CoNCo) stratified by patient status on last contact. (e) Gene ontology terms found enriched among CoNCo genes.
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(Figure 3d). These data highlight the importance of considering the
consequences of splicing when seeking expression signatures using
transcription data.
Finally, we asked whether these splicing changes in tumour
samples were associated with specific pathways, and found
significant enrichment for DNA damage and repair pathways, as
well as alternative splicing (‘Response to DNA Damage Stimulus’,
‘DNA Repair’ and ‘RNA Splicing’ gene ontology (GO) categories;
Benjamini and Hochberg corrected P value o0.01; Figure 3e). A
significant proportion of these loci were also known downstream
targets of TP53 (Ingenuity; IPA; P value of overlap: o10− 6).
DISCUSSION
Although hypoxia-dependent splicing changes have been
reported for individual loci,30–32 there has been no evidence on
how widely applicable the phenomenon may be.33 Here we
identified a comprehensive remodelling of transcript structures in
response to hypoxia, encompassing significant changes in the
levels of 12% of all protein-coding transcripts, and a switch to a
different major isoform at 7% of all protein-coding loci. We
observed similar changes in colorectal carcinomas and a
widespread switch to noncoding isoforms that correlated strongly
with tumour status at last contact. Many of these changes
involved expression of novel transcripts not present in the
ENSEMBL reference annotation database.
While splicing to remodel the proteome is well understood to
be a critical process through which cells achieve increased protein
diversity,34 we have identified a novel role for splicing in which
switching between noncoding isoforms modulates overall protein
output from a locus. Hypoxia-dependent changes were biased
towards loss of the protein-coding isoform under hypoxia and
consistent with the rapid decline in protein synthesis that
accompanies a shift to hypoxic conditions (Figure 3). Importantly,
loci that changed in this way were significantly enriched for
specific pathways, including those that respond to DNA damage.
The effects observed are, therefore, not simply the result of overall
loss of fidelity in the splicing machinery, but rather a consequence
of its coordinated reprogramming, and confirming the importance
of identifying switching events in isoform expression.35 Alto-
gether, these data indicate the presence of a tightly regulated
pathway, and are therefore important in the context of recent
reports that somatic single-nucleotide variants can result in
aberrant splicing patterns, including intron retention, that
deactivate tumour suppressor genes.36 Our data indicate that
these splicing patterns may occur naturally as part of normal
regulatory processes, and that single-nucleotide variants provide a
mechanism by which cancer cells can hijack these pathways to
subvert normal mechanisms of control. This transformation of the
coding competence of the transcriptome occurs in parallel with
changes to other regulatory pathways including epigenetic
modifiers and multiple kinases, thus providing further opportu-
nities to rewire cancer-signalling pathways.37
Both HDAC6 and TP53BP1 exhibited a significant decline in
protein level concomitant with increased intron retention.
These data, together with coding–noncoding splicing changes
to multiple key components of the Fanconi Anemia pathway
(MU31, FANCB, FANCG, FANCM, ATRIP, POLG and RPA1),
the nucleotide excision repair pathway (AQR, PLD1, ERCC2, LIG1,
RPA1, CCNH, RNF11, ACTL6A, RFC1, REV1, ACRT8 and GTF2H2)
and the double-strand break repair pathway (RAD9, WRN,
SMARCA5, UIMC1, RFC1, MUS81, POLD1, ATRIP, CHEK1, CLSPN,
BABM1, TP53BP1, RPA1, REV1, CDK2 and RAD52), together
reveal a hitherto unanticipated role for alternative splicing in
modulating the DNA damage response through action both at
critical regulators (e.g., HDAC6, TP53BP1; Figure 2 and the G2-M
checkpoint kinase CHEK1) and by modulating the level of proteins
throughout the pathway.
Hypoxia-dependent increases in genetic instability have previously
been suggested as a driver of a ‘mutator phenotype’,38 in which
elevated mutation rates increase clonal diversity, leading to a greater
likelihood of the expression of a clone with genetic changes that
confer a proliferative advantage.24 Taken together, our data suggest
that a shift to noncoding expression in response to hypoxia may
provide a novel, important, and unanticipated mechanisms by which
these processes are mediated.
Our reanalysis of TCGA data also revealed a striking signature of
outcome in which a switch to a noncoding major isoform at
multiple protein coding loci is associated with patients annotated
as ‘with tumour at last contact’. Importantly, these changes are not
detected using gene-level expression summaries, as overall RNA
levels from these loci do not change substantially. Our findings
have clear implications for the analysis of expression data and the
development of RNA-based signatures and biomarkers in both
diagnostics and personalised medicine.
MATERIALS AND METHODS
Cell culture
HCT116 were cultured in RPMI-1640 media (Life Technologies, Grand
Island, NY, USA) supplemented with 10% FBS (fetal bovine serum; Biosera,
Sussex, UK, FB-1000/500). All cells were maintained in a humidified
atmosphere at 37 °C and 5% CO2. For hypoxia treatment, the HCT116 cell
line was cultured in 1% O2 in an Invivo2 hypoxia workstation 4000
(Biotrace, Fred Baker, Runcorn, UK) for the given time course 24 h after
plating. Cells were obtained from ATCC tested and authenticated using
multiplex PCR (Powerplex 21, Promega, Madison, WI, USA; 15.03.10).
Cell cycle analysis by flow cytometry
Cells were fixed with 70% ethanol. Briefly, cells were collected and washed
in PBS–2%BSA twice and resuspended to a concentration of 3–6 mill/ml.
500 ml were taken and 5 ml cold 70% ethanol was added dropwise to the
cells whilst gently vortexing to prevent cell clumping. Cells were fixed at 4 °C
for 1 h and stored at − 20 °C until ready for FACS analysis. The cells were
stained with FxCycle PI/RNase Staining Solution solution (Life Technologies
F10797) according to the manufacturer’s protocol and the cells were
analysed using the BD FACS Canto 11 system with the BD FACS Diva
software version 8 (BD Biosciences, San Jose, CA, USA). Data analysis was
performed using the Modfit4 software (Verity Software House, Topsham, ME,
USA).
Protein extraction and western blotting
Protein was extracted by washing cells in ice-cold phosphate-buffered
saline (PBS) and scraping cells in ice-cold cell lysis buffer (9803s New
England Biolabs, Ipswich, MA, USA) supplemented with PMSF (Sigma,
St Louis, MO, USA, 93482) and protease inhibitors (Roche Diagnostics Corp.,
Indianapolis, IN, USA, complete EDTA free 11,873,580,001). The sample was
centrifuged at 4 °C 13,000 r.p.m. for 10 min and supernatent was
preserved. Total protein per sample of 50 μg was resolved by SDS-
polyacrylamide gel electrophoresis 10% NuPage gels (Invitrogen, Carlsbad,
CA, USA) and transferred electrophoretically to Immobilon-P (Millipore,
Temecula, CA, USA). The membrane was blocked in 5%milk PBS-T for
30 min and blotted overnight with HDAC6 antibody (1/1,000 NEB 7558S),
TP53BP1 (1/1,000 AT4311a Generon mouse monoclonal antibody), or
tubulin antibody (1/5,000 Sigma T6199). Detection was performed using a
peroxidase-conjugated anti-rabbit or anti-mouse IgG (Amersham
Biosciences Pharmacia, Piscataway, NJ, USA) and chemiluminescence
visualisation (ECL+, Amersham Biosciences) was used according to the
manufacturer’s instructions. Quantification of western blot signals was
performed using the Chemi Genius Bioimaging system (Syngene, Frderick,
MD, USA) and the Chemi genius gel documentation and analysis system.
RNA extraction and construction of sequencing libraries
RNA was extracted using the Qiagen Qiashredder kit (79654) and the
Qiagen RNeasy Mini Kit (74104) as per the manufacturer’s instructions
(Qiagen Inc., Valencia, CA, USA). The RNA was DNase treated following the
protocol in the RNeasy Mini Kit with Qiagen RNase-free DNase I (79254).
Indexed PolyA libraries were prepared using 1 μg of total RNA and 13
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cycles of amplification in the NEB Next Ultra Directional RNA Library Prep
Kit for Illumina (New England Biolabs, Cat No: E7420S). RNA Integrity Values
scores were49 for all samples. Libraries were quantified by qPCR using a
Kapa Library Quantification Kit for Illumina sequencing platforms (Kapa
Biosystems, Wilmington, MA, USA, Cat No: KK4835). Pooled libraries were
clustered at 15 pmol/l on the cBot and 2× 100 bp sequencing was carried
out using the High Throughput mode of a HiSeq 2500 using TruSeq SBS Kit
v3 chemistry (Illumina)
Data analysis
All statistical analysis including t-tests and Wilcoxon’s tests, were
performed in R. Time-course data: 100mer paired reads were aligned to
the human genome (hg19) using Mapsplice (v2.1.4; default parameters),18
which has previously been shown to perform well for de novo splice
junction identification.39 An average of 43.8 M (27.5–58.2 M) read-pairs per
sample mapped to the genome in the correct orientation and
appropriately spaced, corresponding to ~ 90% of the total reads
sequenced. Alternative splicing analysis can be affected by contamination
from premature and pre-mRNA transcripts in the poly(A) selected pool.
This is manifested by increased numbers of reads mapping to introns. We
calculated the read distribution in different regions including exons,
introns, untranslated regions, promoters and intergenic regions derived
from the genomic annotations in Ensembl (hg19), and found the majority
of reads fell within exons and untranslated regions, whereas only a very
small proportion of reads mapped to introns. Further, these data were
consistent across the samples and there were no significant differences in
these overall QC values between replicate groups (Supplementary Table 1).
Transcript models were derived for each sample independently using
Cufflinks (v2.2.0; with default parameters, except to specify strand
specificity; https://github.com/cole-trapnell-lab/cufflinks). Resultant models
were then merged using Cuffmerge to provide a global model and to
classify transcripts as novel, or known, when they mapped to ENSEMBL
(v74; http://www.ensembl.org). In order to minimise false positives, a
deliberately stringent filtration was used in order to call novel transcripts:
Gene models were first filtered to keep transcripts only when an exon
junction was supported by at least 2 reads in at least two samples. This
filtration step removed a large proportion of potentially unreliable exon
junctions, such that following this step 68.2% of exon junctions completely
matched Ensembl annotations, whereas 30% differed in either the start or
end site but not both and only 1.8% of which were completely novel
(Supplementary Table 1). The transcripts were also filtered for overall
normalised expression levels, with only transcripts with fragments per
kilobase mapped (FPKM)40.5 in at least three samples being retained for
analysis. These transcripts were subsequently classified according to
transcript type and provided in the Supplementary Table 2. The 53,936
transcripts (15,334 genes) were used to obtain gene-level counts using the
RsubRead package40 in R and supplied to edgeR41 to call differential
expression (absolute fold-change 42 relative to 0 h; false discovery rate
(FDR)o1%) at each time point. Annotation was supplied by the
Bioconductor package annmap.42
Gene ontology enrichment analysis
Functional enrichment analysis was performed using the Goseq package43
in R to identify statistically enriched GO terms44 (Hypergeometric test:
Benjamini and Hochberg corrected P value o0.01). Non-redundant GO
terms were obtained by retaining only one representative term from GO
with high semantic similarity, derived using GOSemSim package45 in R.
Detection of alternative splicing
Alternative splicing was detected at both transcript level and exon level.
Differential splicing at the exon level was performed for 24 h samples
(in hypoxia) versus 0 h using the DEXSeq package in R. DEXSeq uses
transcript annotations of each gene to split them non-overlapping bins
(exon counting bins) and then uses Generalized Linear Models to identify
differentially used exon counting bins. Only exon counting bins that were
at least 50-bp long, with mean exonic counts41 and satisfied a FDR cutoff
of 5% were considered as differentially used. Differential splicing at the
transcript level was performed for 24-h samples (in hypoxia) versus 0 h
using the Cuffdiff program within Cufflinks. In addition to detecting
differential splicing, Cuffdiff also reports statistically significant differential
promoter usage and differential coding sequence usage. Statistically
significant changes were detected at a FDR cutoff of 5%. Following this, the
alternative splicing events were annotated into 5 major categories, Exon
Skipping, Mutually Exclusive Exons, Intron Retention, Alternative 3′ Splice
Sites and Alternative 5′ Splice Sites, using MATS (3.0.8). The splicing events
from MATS were detected using both read information and exon junction
data and filtered for statistically significant events (FDRo1%).
Analysis of TCGA data
Splice-aware aligned RNAseq data (BAM files) of Colorectal cancer cohort
(COAD)29 comprising of 458 tumour samples and 41 normal samples along
with corresponding clinical data was obtained from TCGA. Gene and
transcripts quantification and normalisation was performed using the
standard Cufflinks pipeline and the annotations in Ensembl (v74). In all
cases exon-mapping reads substantially outnumbered intron-mapping
reads: median exon/intron ratio per kb = 557.5, with minimal difference
between HiSeq 2000 and GAII processed samples (543.7 and 637.6,
respectively).
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